---
layout: default
title: Cobicistat
description: "Cobicistat çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 3 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 51
evidence_level: L5
indication_count: 3
---

# Cobicistat

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>3</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Cobicistat è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Cobicistat å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Cobicistat æ˜¯ä¸€ç¨®è—¥å‹•å­¸å¢å¼·åŠ‘ï¼ˆpharmacokinetic enhancerï¼‰ï¼Œå°ˆé–€ç”¨æ–¼ HIV æ²»ç™‚ä¸­å¢åŠ è›‹ç™½é…¶æŠ‘åˆ¶åŠ‘çš„è¡€ä¸­æ¿ƒåº¦ï¼ŒTxGNN é æ¸¬å…¶å°å…¶ä»–å…ç–«ç¼ºä¹ç—…æ¯’æ„ŸæŸ“æœ‰ç™‚æ•ˆï¼Œä½†é€™äº›é æ¸¬è‡¨åºŠæ„ç¾©æœ‰é™ä¸”ç¼ºä¹å¯¦éš›æ‡‰ç”¨åƒ¹å€¼ã€‚
</p>


---

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Cobicistat |
| DrugBank ID | DB09065 |
| å°ç£å•†å“å | ä¿¡æ¾¤åŠ›è†œè¡£éŒ  (Symtuza)ã€æ·æ‰¶åº·è†œè¡£éŒ  (Genvoya)ã€æ™®æ¾¤åŠ›è†œè¡£éŒ  (Prezcobix) |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | HIV-1 æ„ŸæŸ“ï¼ˆèˆ‡å…¶ä»–æŠ—åè½‰éŒ„ç—…æ¯’è—¥ç‰©ä½µç”¨ï¼‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | HIV infectious diseaseã€simian immunodeficiency virus infectionã€feline acquired immunodeficiency syndrome |
| æœ€é«˜é æ¸¬åˆ†æ•¸ | 0.999 (simian/feline immunodeficiency) |
| è­‰æ“šç­‰ç´š | L5 (åƒ…é æ¸¬ï¼Œç„¡è‡¨åºŠæ„ç¾©) |

---

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼ˆæˆ–ä¸åˆç†ï¼‰

### Cobicistat çš„ç‰¹æ®Šè—¥ç†è§’è‰²

Cobicistat æœ¬èº« **ä¸å…·æœ‰æŠ—ç—…æ¯’æ´»æ€§**ï¼Œå…¶ä½œç”¨æ˜¯ï¼š

1. **CYP3A æŠ‘åˆ¶**ï¼šå¼·æ•ˆæŠ‘åˆ¶ CYP3A é…µç´ ï¼Œå»¶ç·©è›‹ç™½é…¶æŠ‘åˆ¶åŠ‘ï¼ˆå¦‚ darunavirã€atazanavirï¼‰åŠæ•´åˆé…¶æŠ‘åˆ¶åŠ‘ï¼ˆå¦‚ elvitegravirï¼‰çš„ä»£è¬
2. **è—¥å‹•å­¸å¢å¼·**ï¼šä½¿ä½µç”¨è—¥ç‰©ç¶­æŒæœ‰æ•ˆè¡€ä¸­æ¿ƒåº¦ï¼Œæ¸›å°‘çµ¦è—¥é »ç‡

### é æ¸¬åˆ†æ

| é æ¸¬é©æ‡‰ç—‡ | åˆ†æ |
|------------|------|
| Simian immunodeficiency virus (SIV) | çŸ¥è­˜åœ–è­œåŸºæ–¼ HIV é—œè¯æ¨æ–·ï¼Œä½† cobicistat æœ¬èº«ç„¡æŠ—ç—…æ¯’ä½œç”¨ |
| Feline acquired immunodeficiency syndrome (FIV) | åŒä¸Šï¼Œä¸”ç¸é†«é ˜åŸŸç„¡æ­¤æ‡‰ç”¨ |
| ç¥ç¶“ç™¼è‚²éšœç¤™ | èˆ‡ cobicistat ä½œç”¨æ©Ÿè½‰å®Œå…¨ç„¡é—œï¼Œå±¬èª¤åˆ¤ |

**çµè«–**ï¼šé€™äº›é æ¸¬åæ˜ äº†çŸ¥è­˜åœ–è­œæ–¹æ³•çš„å±€é™æ€§ - å®ƒåŸºæ–¼é—œè¯æ€§è€Œéå› æœæ€§ï¼Œæœªèƒ½å€åˆ†ã€Œè—¥å‹•å­¸å¢å¼·åŠ‘ã€èˆ‡ã€ŒæŠ—ç—…æ¯’è—¥ç‰©ã€çš„æœ¬è³ªå·®ç•°ã€‚

---

## è‡¨åºŠè©¦é©—è­‰æ“š

**ç„¡** é‡å°é æ¸¬é©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ã€‚

æ‰€æœ‰ cobicistat ç›¸é—œè©¦é©—éƒ½æ˜¯é—œæ–¼å…¶åœ¨ HIV æ²»ç™‚ä¸­ä½œç‚ºè—¥å‹•å­¸å¢å¼·åŠ‘çš„è§’è‰²ã€‚

---

## æ–‡ç»è­‰æ“š

**ç„¡** æ”¯æŒé æ¸¬é©æ‡‰ç—‡çš„æ–‡ç»ã€‚

Cobicistat çš„æ‰€æœ‰æ–‡ç»éƒ½èšç„¦æ–¼å…¶è—¥å‹•å­¸å¢å¼·ä½œç”¨ï¼Œè€Œéç›´æ¥æ²»ç™‚æ•ˆæœã€‚

---

## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | æˆåˆ†çµ„æˆ | é©æ‡‰ç—‡ | ç‹€æ…‹ |
|------------|--------|----------|--------|------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027613è™Ÿ | ä¿¡æ¾¤åŠ›è†œè¡£éŒ  (Symtuza) | Darunavir + Cobicistat + Emtricitabine + Tenofovir alafenamide | HIV-1 æ„ŸæŸ“ | æœ‰æ•ˆ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027001è™Ÿ | æ·æ‰¶åº·è†œè¡£éŒ  (Genvoya) | Elvitegravir + Cobicistat + Emtricitabine + Tenofovir alafenamide | HIV-1 æ„ŸæŸ“ | æœ‰æ•ˆ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027263è™Ÿ | æ™®æ¾¤åŠ›è†œè¡£éŒ  (Prezcobix) | Darunavir + Cobicistat | HIV-1 æ„ŸæŸ“ | æœ‰æ•ˆ |

**é‡é»**ï¼šCobicistat åœ¨å°ç£åƒ…ä»¥è¤‡æ–¹å½¢å¼ä¸Šå¸‚ï¼Œä¸ä½œç‚ºå–®æ–¹è—¥å“ä½¿ç”¨ã€‚

---

## å®‰å…¨æ€§è€ƒé‡

### é‡è¦è—¥ç‰©äº¤äº’ä½œç”¨

Cobicistat æ˜¯å¼·æ•ˆ CYP3A æŠ‘åˆ¶åŠ‘ï¼Œè—¥ç‰©äº¤äº’ä½œç”¨æ¥µç‚ºå»£æ³›ä¸”è¤‡é›œï¼š

| äº¤äº’ä½œç”¨é¡å‹ | ä»£è¡¨è—¥ç‰© | åš´é‡ç¨‹åº¦ |
|--------------|----------|----------|
| **ç¦å¿Œä½µç”¨** | Simvastatin, Alfuzosin, Cisapride | Major |
| é¡å›ºé†‡ | Triamcinolone, Budesonide | Major (å¯èƒ½å°è‡´åº«æ¬£ç—‡å€™ç¾¤) |
| é®ç—›åŠ‘ | Fentanyl, Alfentanil, Hydrocodone | Major |
| å¿ƒè¡€ç®¡è—¥ç‰© | Amiodarone, Apixaban | Major |
| æŠ—ç™²ç™‡è—¥ | Fosphenytoin | Major |
| é®éœå®‰çœ è—¥ | Alprazolam, Triazolam | Moderate |

### ç‰¹åˆ¥è­¦èª

1. **è…åŠŸèƒ½ç›£æ¸¬**ï¼šCobicistat æœƒå½±éŸ¿è‚Œé…¸é…åˆ†æ³Œï¼Œå¯èƒ½é€ æˆè¡€æ¸…è‚Œé…¸é…å‡æ€§ä¸Šå‡
2. **éª¨è³ªå¯†åº¦**ï¼šé•·æœŸä½¿ç”¨éœ€ç›£æ¸¬éª¨å¯†åº¦
3. **è„‚è³ªä»£è¬**ï¼šå¯èƒ½å½±éŸ¿è¡€è„‚

---

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

**è‘¡è„æŸš** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šè‘¡è„æŸšå¯èƒ½å¢å¼· CYP3A4 æŠ‘åˆ¶ä½œç”¨
- å»ºè­°ï¼šé¿å…è‘¡è„æŸš

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸ”´ Major
- å½±éŸ¿ï¼šè–ç´„ç¿°è‰é™ä½ Cobicistat åŠå…¶å¢å¼·è—¥ç‰©çš„è¡€ä¸­æ¿ƒåº¦
- å»ºè­°ï¼šçµ•å°ç¦æ­¢ä½µç”¨



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- Cobicistat has shown to decrease creatinine clearance without affecting actual renal glomerular function and no dose adjustment is required in patients with renal impairment, including those with severe renal impairment.  However, this effect should ...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬è©•ä¼°

| è©•ä¼°é …ç›® | çµæœ |
|----------|------|
| æ©Ÿè½‰åˆç†æ€§ | ä¸åˆç† - Cobicistat ç„¡ç›´æ¥æŠ—ç—…æ¯’æ´»æ€§ |
| è‡¨åºŠè­‰æ“š | ç„¡ |
| æ–‡ç»æ”¯æŒ | ç„¡ |
| æ•´é«”è­‰æ“šç­‰ç´š | **L5 (åƒ…é æ¸¬ï¼Œç„¡è‡¨åºŠæ„ç¾©)** |

### æ–¹æ³•å­¸åæ€

æ­¤è—¥ç‰©çš„é æ¸¬çµæœå‡¸é¡¯äº†çŸ¥è­˜åœ–è­œæ–¹æ³•çš„é‡è¦é™åˆ¶ï¼š

1. **æœªå€åˆ†è—¥ç‰©è§’è‰²**ï¼šå°‡è—¥å‹•å­¸å¢å¼·åŠ‘èª¤åˆ¤ç‚ºå…·æœ‰ç›´æ¥æ²»ç™‚ä½œç”¨
2. **é—œè¯æ€§ vs å› æœæ€§**ï¼šcobicistat èˆ‡ HIV è—¥ç‰©çš„é—œè¯è¢«éŒ¯èª¤å»¶ä¼¸è‡³å…¶ä»–å…ç–«ç¼ºä¹ç—‡
3. **å‹•ç‰©ç–¾ç—…é æ¸¬**ï¼šSIV å’Œ FIV çš„é æ¸¬åœ¨äººé¡é†«å­¸ç„¡å¯¦éš›æ‡‰ç”¨åƒ¹å€¼

### å»ºè­°

1. **ä¸å»ºè­°ä»»ä½•è‡¨åºŠå»¶ä¼¸ä½¿ç”¨**ï¼šé æ¸¬çµæœç„¡ç§‘å­¸ä¾æ“š
2. **æ–¹æ³•æ”¹é€²æ–¹å‘**ï¼šæœªä¾†çŸ¥è­˜åœ–è­œæ¨¡å‹æ‡‰ç´å…¥è—¥ç‰©ä½œç”¨é¡å‹æ¨™è¨»ï¼Œå€åˆ†ç›´æ¥æ²»ç™‚æ•ˆæœèˆ‡è¼”åŠ©å¢å¼·ä½œç”¨
3. **ç¶­æŒç¾æœ‰é©æ‡‰ç—‡**ï¼šCobicistat æ‡‰ç¹¼çºŒåƒ…ç”¨æ–¼å…¶æ ¸å‡†çš„ HIV æ²»ç™‚è—¥å‹•å­¸å¢å¼·è§’è‰²

---

*æœ¬ç­†è¨˜åƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚ä»»ä½•ç”¨è—¥æ±ºç­–æ‡‰è«®è©¢å°ˆæ¥­é†«ç™‚äººå“¡ã€‚*

*æœ€å¾Œæ›´æ–°ï¼š2026-02-11*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Clomipramine]({{ "/drugs/clomipramine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ipilimumab]({{ "/drugs/ipilimumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Polyethylene Glycol]({{ "/drugs/polyethylene_glycol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Isoleucine]({{ "/drugs/isoleucine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ethynodiol Diacetate]({{ "/drugs/ethynodiol_diacetate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Cobicistatè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/cobicistat/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_cobicistat,
  title = {Cobicistatè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/cobicistat/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
